Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Kailin XuJiang CaoWeiying GuMing ShiJianping LanZhiling YanLai JinJieyun XiaSha MaYang LiuHujun LiBin PanWei ChenXiaoming FeiChunling WangXiaobao XieLiang YuGang WangHuizhong LiGuangjun JingHai ChengFeng ZhuHaiying SunWei SangDepeng LiZhenyu LiJunnian ZhengPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with R/R MM, with a median progression-free survival of 18.3 months and a manageable long-term safety profile.